GSM5359444
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.490
- ANGIOGENESIS+0.460
- TNFA_SIGNALING_VIA_NFKB+0.350
- CHOLESTEROL_HOMEOSTASIS+0.340
- PROTEIN_SECRETION+0.340
- ADIPOGENESIS+0.320
- MTORC1_SIGNALING+0.320
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.230
- PEROXISOME+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- E2F_TARGETS-0.360
- MITOTIC_SPINDLE-0.340
- G2M_CHECKPOINT-0.310
- INTERFERON_GAMMA_RESPONSE-0.260
- ALLOGRAFT_REJECTION-0.180
- HEME_METABOLISM-0.160
- DNA_REPAIR-0.110
- IL2_STAT5_SIGNALING-0.110
- SPERMATOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | da1c4d8d-b07a-4aa1-8360-1c140ca16327 | — | — | 0.745 |
| 2 | SRR8943018 | — | — | 0.741 |
| 3 | SRR1313101 | — | A | 0.738 |
| 4 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.729 |
| 5 | MNG1073 | — | — | 0.724 |
| 6 | R260 | — | — | 0.723 |
| 7 | MBCProject_1151_T1_RNA | — | B | 0.719 |
| 8 | MNG754 | — | — | 0.717 |
| 9 | BSR_06_0059_A2_S99 | — | F | 0.714 |
| 10 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.707 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |